Skip to content

Study · Randomized controlled trial · n = 13 · 2016

9 results

Short-term effects of teriparatide versus placebo on bone biomarkers, structure, and fracture healing in women with lower-extremity stress fractures: A pilot study.

Almirol EA, Chi LY, Khurana B, Hurwitz S, Bluman EM, Chiodo C, Matzkin E, Baima J, LeBoff MS

Journal of clinical & translational endocrinology30 May 2016Cited by 30 (Europe PMC)

PMID29067229 (opens in a new tab)PMCIDPMC5644467 (opens in a new tab)DOI10.1016/j.jcte.2016.05.004 (opens in a new tab)PepBankPUB-29067229
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with stress fractures, teriparatide increased P1NP more than placebo after treatment.

    In plain wordsIn premenopausal women with stress fractures, teriparatide increased a bone formation marker more than placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseP1NP
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg · subcutaneous · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    After 8 weeks of treatment, bone biomarkers P1NP and OC increased more in the TPTD- versus placebo-treated group (both p ≤ 0.01), resulting in a marked anabolic window (p ≤ 0.05).
    1 context sentence
    Summary · context
    Premenopausal women with acute lower-extremity stress fractures were randomized to injection of TPTD 20-µg subcutaneous (s.c.) (n = 6) or placebo s.c. (n = 7) for 8 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with stress fractures, teriparatide increased osteocalcin more than placebo after treatment.

    In plain wordsIn premenopausal women with stress fractures, teriparatide increased osteocalcin more than placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseOsteocalcin
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg · subcutaneous · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    After 8 weeks of treatment, bone biomarkers P1NP and OC increased more in the TPTD- versus placebo-treated group (both p ≤ 0.01), resulting in a marked anabolic window (p ≤ 0.05).
    1 context sentence
    Summary · context
    Premenopausal women with acute lower-extremity stress fractures were randomized to injection of TPTD 20-µg subcutaneous (s.c.) (n = 6) or placebo s.c. (n = 7) for 8 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with stress fractures, teriparatide produced a marked anabolic window versus placebo.

    In plain wordsIn women with stress fractures, teriparatide increased the gap between bone formation and resorption markers versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseAnabolic window
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg · subcutaneous · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    After 8 weeks of treatment, bone biomarkers P1NP and OC increased more in the TPTD- versus placebo-treated group (both p ≤ 0.01), resulting in a marked anabolic window (p ≤ 0.05).
    2 context sentences
    Summary · context
    The area between the percent change of P1NP and CTX over study duration is defined as the anabolic window.
    Summary · context
    Premenopausal women with acute lower-extremity stress fractures were randomized to injection of TPTD 20-µg subcutaneous (s.c.) (n = 6) or placebo s.c. (n = 7) for 8 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with stress fractures, teriparatide produced a larger cortical area at the weight-bearing tibia than placebo.

    In plain wordsIn women with stress fractures, the outer bone area at the weight-bearing tibia was larger with teriparatide than placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial cortical area
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg · subcutaneous · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Results from pQCT demonstrated that TPTD-treated women showed a larger cortical area and thickness compared to placebo at the weight bearing tibial site, while placebo-treated women had a greater total tibia and cortical density.
    1 context sentence
    Summary · context
    Premenopausal women with acute lower-extremity stress fractures were randomized to injection of TPTD 20-µg subcutaneous (s.c.) (n = 6) or placebo s.c. (n = 7) for 8 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with stress fractures, teriparatide produced greater cortical thickness at the weight-bearing tibia than placebo.

    In plain wordsIn women with stress fractures, the outer bone layer at the weight-bearing tibia was thicker with teriparatide than placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial cortical thickness
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg · subcutaneous · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Results from pQCT demonstrated that TPTD-treated women showed a larger cortical area and thickness compared to placebo at the weight bearing tibial site, while placebo-treated women had a greater total tibia and cortical density.
    1 context sentence
    Summary · context
    Premenopausal women with acute lower-extremity stress fractures were randomized to injection of TPTD 20-µg subcutaneous (s.c.) (n = 6) or placebo s.c. (n = 7) for 8 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with stress fractures, total tibial density was lower with teriparatide than placebo.

    In plain wordsIn women with stress fractures, total shinbone density was lower with teriparatide than placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTotal tibial density
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg · subcutaneous · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Results from pQCT demonstrated that TPTD-treated women showed a larger cortical area and thickness compared to placebo at the weight bearing tibial site, while placebo-treated women had a greater total tibia and cortical density.
    1 context sentence
    Summary · context
    Premenopausal women with acute lower-extremity stress fractures were randomized to injection of TPTD 20-µg subcutaneous (s.c.) (n = 6) or placebo s.c. (n = 7) for 8 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with stress fractures, tibial cortical density was lower with teriparatide than placebo.

    In plain wordsIn women with stress fractures, density of the outer shinbone layer was lower with teriparatide than placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTibial cortical density
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg · subcutaneous · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Results from pQCT demonstrated that TPTD-treated women showed a larger cortical area and thickness compared to placebo at the weight bearing tibial site, while placebo-treated women had a greater total tibia and cortical density.
    1 context sentence
    Summary · context
    Premenopausal women with acute lower-extremity stress fractures were randomized to injection of TPTD 20-µg subcutaneous (s.c.) (n = 6) or placebo s.c. (n = 7) for 8 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In women with stress fractures, radial site changes did not differ between teriparatide and placebo.

    In plain wordsIn women with stress fractures, changes at forearm bone sites did not differ between teriparatide and placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeRadial structural changes
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg · subcutaneous · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    No changes at the radial sites were observed between groups.
    1 context sentence
    Summary · context
    Premenopausal women with acute lower-extremity stress fractures were randomized to injection of TPTD 20-µg subcutaneous (s.c.) (n = 6) or placebo s.c. (n = 7) for 8 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In women with stress fractures, MRI improvement or healing occurred in 83.3% with teriparatide versus 57.1% with placebo, without significant difference.

    In plain wordsIn women with stress fractures, MRI healing or improvement did not differ significantly between teriparatide and placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeMRI fracture improvement or healing
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg · subcutaneous · 8 weeksAs given in this study (human).

    Measurements

    Improved or healed
    83.3%
    teriparatide
    Improved or healed
    57.1%
    placebo

    Source sentences

    Summary
    According to MRI, 83.3% of the TPTD- and 57.1% of the placebo-treated group had improved or healed stress fractures (p = 0.18).
    1 context sentence
    Summary · context
    Premenopausal women with acute lower-extremity stress fractures were randomized to injection of TPTD 20-µg subcutaneous (s.c.) (n = 6) or placebo s.c. (n = 7) for 8 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.